GLP-1s are changing benefits decisions.
Here’s how to stay in control.
Real promise for members, real pressure for clients
GLP‑1 medications continue to reshape weight management, bringing real promise for members and real pressure for clients.
These therapies help members lose weight and improve their overall health, but they also raise questions about side effects, long‑term outcomes and how quickly the market is evolving. And as demand keeps growing — fueled by new products and indications — managing them has become more complex. Many clients are asking, “How do we support members without losing control of costs?”
GLP-1s: What we know, what’s uncertain and what’s coming next
If you’re trying to understand how GLP‑1s will impact your pharmacy spend in 2026, and what options you have to manage it, you’re not alone.
In 2026 GLP‑1 outlook: A strategic roadmap to manage spend and trend, Joshua Fredell, Senior Vice President and Head of PBM & Specialty Product Innovation at CVS Caremark, breaks down what’s happening in the GLP-1 market today: what we know, what’s uncertain and what’s likely coming next.
Josh takes us behind the headlines to better understand why more people are taking GLP-1s, where costs are actually getting better and the practical steps you can take right now to balance affordability, access and outcomes.
